MRI-DTI look at the urethral sphincter ring and prostate base shape

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center, observational imaging study using diffusion tensor imaging to visualize the ring-like structure of the male urethral internal sphincter and to explore its relationship with prostate base morphology. Participants include men undergoing pelvic, seminal vesicle, or prostate-related MRI-DTI for clinical reasons, with subgroups for those with benign prostatic enlargement or prostate cancer planned for androgen deprivation therapy. The study combines DTI with T2-weighted imaging, using fiber tracking and 3D reconstruction to characterize spatial relationships in the bladder neck, prostate base, and proximal urethra. It aims to provide in vivo descriptions of sphincter morphology under varying prostate conditions and during ADT follow-up where applicable.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male participants undergoing clinically indicated pelvic, seminal vesicle, or prostate-related MRI-DTI examination.
2. Participants with adequate T2-weighted MRI and DTI data for post-processing and quantitative assessment of the bladder neck, prostate base, and proximal urethral region.
3. Participants in the cross-sectional imaging cohort may include men undergoing MRI for suspected cryptorchidism, suspected seminal vesiculitis, benign prostatic enlargement, or other clinically indicated pelvic or prostate-related evaluations.
4. Participants in the ADT paired follow-up cohort must have prostate cancer and be scheduled to receive androgen deprivation therapy, with MRI-DTI planned before treatment and during follow-up after ADT.
5. Participants must be able to comply with MRI examination procedures.
6. Written informed consent will be obtained when required by the approved study protocol.

Exclusion Criteria:

1. Contraindications to MRI, including but not limited to incompatible metallic implants, severe claustrophobia, or other conditions preventing MRI examination.
2. Known neurogenic bladder dysfunction, including spinal cord injury, multiple sclerosis, Parkinson disease, or other neurological disorders that may significantly affect lower urinary tract function.
3. History of pelvic radiotherapy.
4. History of urethral reconstruction, sphincter surgery, or other prior surgery that substantially alters the bladder neck, proximal urethra, or prostate base anatomy.
5. Severe cardiopulmonary dysfunction, cognitive impairment, psychiatric disorder, or other conditions preventing cooperation with MRI examination or study procedures.
6. Use of medications or treatments within the previous 3 months that may substantially affect neuromuscular function of the lower urinary tract, as judged by the investigators.
7. Poor image quality or failed post-processing that prevents reliable visualization or measurement of the urethral internal sphincter ring.

Where it's running

• JiangsuTaizhouPH
  Taizhou, Jiangsu, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sonablate HIFU Registry for Prostate Cancer and BPH

  This registry collects real-world data from men treated with Sonablate HIFU to see how well it works and how it affects urinary and sexual function over the long term.

  Recruiting Sonablate · Indianapolis, Indiana · NCT07757490

• Bioblation: Combined biopsy and laser treatment for prostate symptoms and suspected cancer

  A single-session procedure (Bioblation) combines a trans-perineal prostate biopsy with laser ablation to relieve severe LUTS and treat likely low- to favorable intermediate-risk prostate cancer.

  Recruiting Benha University · Banhā, Qalyubia Governorate · NCT07526675

• Treatment for male overactive bladder using sacral neuromodulation

  This study is testing a new device to see if it can help men with overactive bladder feel better after prostate surgery or radiation therapy.

  Recruiting at 21 sites Axonics, Inc. · Birmingham, Alabama and 22 other locations · NCT06511141

• Registry for patients undergoing TULSA procedure for prostate conditions

  This study is tracking patients who have had the TULSA procedure for prostate issues to see how safe and effective it is and how it affects their quality of life over time.

  Recruiting at 5 sites Profound Medical Inc. · West Hills, California and 4 other locations · NCT05001477

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer

  This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07879820

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.